Impact of lipoatrophy on patient-reported outcomes in antiretroviral-experienced patients.
Lipoatrophy is a noteworthy adverse effect of antiretroviral therapy. A 2-part literature review was conducted to assess the impact of lipoatrophy in HIV-infected persons: the first reviewed the qualitative studies that reported lipoatrophy data, and the second reviewed the clinical studies that recorded patient-reported outcome end points. This literature review provided considerable evidence that lipoatrophy has a negative impact on the psychosocial well-being and health-related quality of life of HIV-infected persons receiving antiretroviral therapy. However, the patient-reported outcome measures used in clinical studies were not lipoatrophy-specific and had limited ability to show real changes in health status associated with lipoatrophy.
Doward
Lynda C
LC
Galen Research Ltd, Manchester, United Kingdom.
Dietz
Birgitta
B
Wilburn
Jeanette
J
McKenna
Stephen P
SP
Bhor
Menaka
M
Rajagopalan
Rukmini
R
D044966:Anti-Retroviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D015658:HIV Infections / Q000188:drug therapy* / Q000523:psychology; D039682:HIV-Associated Lipodystrophy Syndrome / Q000139:chemically induced; D006304:Health Status; D006801:Humans; D036301:Qualitative Research; D011788:Quality of Life; D012307:Risk Factors; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D044966:Anti-Retroviral Agents